These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 16775596)

  • 1. Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice.
    Zheng F; Zeng YJ; Plati AR; Elliot SJ; Berho M; Potier M; Striker LJ; Striker GE
    Kidney Int; 2006 Aug; 70(3):507-14. PubMed ID: 16775596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined therapy of rhein and benazepril on the treatment of diabetic nephropathy in db/db mice.
    Jia ZH; Liu ZH; Zheng JM; Zeng CH; Li LS
    Exp Clin Endocrinol Diabetes; 2007 Oct; 115(9):571-6. PubMed ID: 17943690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
    Jacobsen P; Andersen S; Jensen BR; Parving HH
    J Am Soc Nephrol; 2003 Apr; 14(4):992-9. PubMed ID: 12660333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-converting enzyme inhibition and angiotensin AT1 receptor blockade downregulate angiotensin-converting enzyme expression and attenuate renal injury in streptozotocin-induced diabetic rats.
    Motawi TK; El-Maraghy SA; Senousy MA
    J Biochem Mol Toxicol; 2013 Jul; 27(7):378-87. PubMed ID: 23733546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meprin-alpha in chronic diabetic nephropathy: interaction with the renin-angiotensin axis.
    Mathew R; Futterweit S; Valderrama E; Tarectecan AA; Bylander JE; Bond JS; Trachtman H
    Am J Physiol Renal Physiol; 2005 Oct; 289(4):F911-21. PubMed ID: 15942051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy.
    Williams ME; Bolton WK; Khalifah RG; Degenhardt TP; Schotzinger RJ; McGill JB
    Am J Nephrol; 2007; 27(6):605-14. PubMed ID: 17823506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An additive effect of anti-PAI-1 antibody to ACE inhibitor on slowing the progression of diabetic kidney disease.
    Gu C; Zhang J; Noble NA; Peng XR; Huang Y
    Am J Physiol Renal Physiol; 2016 Nov; 311(5):F852-F863. PubMed ID: 27511457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological blockade of B2-kinin receptor reduces renal protective effect of angiotensin-converting enzyme inhibition in db/db mice model.
    Buléon M; Allard J; Jaafar A; Praddaude F; Dickson Z; Ranera MT; Pecher C; Girolami JP; Tack I
    Am J Physiol Renal Physiol; 2008 May; 294(5):F1249-56. PubMed ID: 18367657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats.
    Kalender B; Oztürk M; Tunçdemir M; Uysal O; Dagistanli FK; Yegenaga I; Erek E
    Acta Histochem; 2002; 104(2):123-30. PubMed ID: 12086332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.
    Kang YS; Ko GJ; Lee MH; Song HK; Han SY; Han KH; Kim HK; Han JY; Cha DR
    Nephrol Dial Transplant; 2009 Jan; 24(1):73-84. PubMed ID: 18682491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined angiotensin II AT1-receptor blockade and angiotensin I-converting enzyme inhibition on survival and cardiac remodeling in chronic heart failure in rats.
    Richer C; Fornes P; Domergue V; De Gasparo M; Giudicelli JF
    J Card Fail; 2001 Sep; 7(3):269-76. PubMed ID: 11561229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enalapril treatment increases T cell number and promotes polarization towards M1-like macrophages locally in diabetic nephropathy.
    Cucak H; Nielsen Fink L; Højgaard Pedersen M; Rosendahl A
    Int Immunopharmacol; 2015 Mar; 25(1):30-42. PubMed ID: 25598292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes.
    Moriyama T; Oka K; Ueda H; Imai E
    Clin Exp Nephrol; 2004 Sep; 8(3):230-6. PubMed ID: 15480900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat.
    Wilkinson-Berka JL; Gibbs NJ; Cooper ME; Skinner SL; Kelly DJ
    Nephrol Dial Transplant; 2001 Jul; 16(7):1343-9. PubMed ID: 11427623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of proteinuria with angiotensin receptor blockers.
    Galle J
    Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S36-43. PubMed ID: 18580865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of enalapril and valsartan in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet.
    Lassila M; Finckenberg P; Pere AK; Krogerus L; Ahonen J; Vapaatalo H; Nurminen ML
    Br J Pharmacol; 2000 Jul; 130(6):1339-47. PubMed ID: 10903974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valsartan slows the progression of diabetic nephropathy in db/db mice via a reduction in podocyte injury, and renal oxidative stress and inflammation.
    Zhou G; Cheung AK; Liu X; Huang Y
    Clin Sci (Lond); 2014 May; 126(10):707-20. PubMed ID: 24195695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors.
    Sugimoto H; Grahovac G; Zeisberg M; Kalluri R
    Diabetes; 2007 Jul; 56(7):1825-33. PubMed ID: 17456853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice.
    Sasaki M; Uehara S; Ohta H; Taguchi K; Kemi M; Nishikibe M; Matsumoto H
    Life Sci; 2004 Jul; 75(7):869-80. PubMed ID: 15183078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat.
    Alderson NL; Chachich ME; Frizzell N; Canning P; Metz TO; Januszewski AS; Youssef NN; Stitt AW; Baynes JW; Thorpe SR
    Diabetologia; 2004 Aug; 47(8):1385-95. PubMed ID: 15309289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.